The major aims of the present study were (1) to select a multiple-unit formulation that matched the in vitro dissolution profile of single-unit sustained-release commercial capsules, (2) to compare the sustaining/controlling efficacy of the selected multiple-unit formulation with that of the single-unit commercial conventional tablet and sustainedrelease capsules, and (3) to determine whether an in vitroin vivo correlation exists for single-and multiple-unit formulations. Ibuprofen (20%-60% wt/wt)-loaded multipleunit polystyrene microparticles were prepared by an emulsionsolvent evaporation method from an aqueous system. The in vitro release profiles obtained in phosphate buffer of pH 6.8 for drug-loaded polystyrene microparticles and for commercial sustained-release capsules (Fenlong-SR, 400 mg) were compared. Since the microparticles with 30% ibuprofen load showed a release profile comparable to that of the Fenlong-SR release profile, the microparticles with this drug load were considered to be the optimized/selected formulation and, therefore, were subjected to stability study and in vivo study in human volunteers. A single-dose oral bioavailability study revealed significant differences in C max , T max , t 1/2a , t 1/2e , K a , K e , and AUC between the conventional tablet and optimized or Fenlong-SR capsule dosage forms. However, all the parameters, with the exception of K a along with relative bioavailability (F) and retard quotient (R Δ ), obtained from the optimized ibuprofenloaded microparticles were lower than that obtained from the commercial Fenlong-SR formulation. Furthermore, linear relationship obtained between the percentages dissolved and absorbed suggests a means to predict in vivo absorption by measuring in vitro dissolution.
INTRODUCTION
Following oral administration, conventional drug delivery systems like tablets and capsules often give rise to inordinately high drug concentrations in plasma, which, in turn, can lead to the emergence of adverse drug reactions. Moreover, if the biological half-life of a drug is short, it requires repeated administration, which leads to patient noncompliance. This is particularly true for chronic dosing, especially in the management of rheumatoid arthritis. Sustained-release dosage forms, single-unit or multiple-unit doses, help physicians to provide optimum treatment by better patient compliance and safer systems with steady-state plasma drug concentrations for the desired period of time. However, multiple-unit formulations like microparticles for oral use allow the administration of much smaller drug amounts than single-unit doses do, by modifying the rate of dissolution of drug and providing a method of releasing the active ingredients at a desired rate. 1 In addition, it has been reported that microparticulate oral dosage forms diffuse rapidly, avoiding the vagaries of gastric emptying throughout the gastrointestinal tract, 2 and thus prevent the exposure of the absorbing mucosa to high drug concentrations during chronic dosing 3 and improve gastric tolerability. 4 Furthermore, local unwanted effects are reduced or eliminated when a gastroresistant polymer is used for microparticle preparation. Ibuprofen was selected as a model drug in this study because reduction of side effects, notably gastrointestinal problems, 5 and prolongation of action of this compound have been desired.
In this study, ibuprofen (20%-60% wt/wt)-loaded multipleunit polystyrene microparticles were prepared by an emulsionsolvent evaporation method from an aqueous system, which was found to be simple and reproducible. 6 The major aims of the study were (1) to select a multiple-unit formulation with an in vitro dissolution profile that matched that of single-unit sustained-release commercial capsules, (2) to compare the sustaining/controlling efficacy of the selected multiple-unit formulation with that of the singleunit commercial conventional tablet and sustained-release capsules, and (3) to determine whether an in vitro-in vivo correlation (IVIVC) exists for single-and multiple-unit formulations.
MATERIALS AND METHODS

Materials
Ibuprofen Indian Pharmacopoeia (M/S Albert-David Ltd, Kolkata, India) and polystyrene (Grade McG-100, general purpose) (Hindustan Polymers, Kolkata, India) were obtained as a sample gift. Conventional tablets of Brufen 400 mg (Boots Pharmaceuticals, Goa, India) and sustained-release capsules of Fenlong-SR 400 mg (SOL Pharmaceuticals, New Delhi, India) and all other chemicals were obtained commercially and used as received.
Methods
Development of Multiple-Unit Dosage Form
Preparation of ibuprofen-loaded polystyrene microparticles by an emulsion-solvent evaporation method from an aqueous system containing methylcellulose as the emulsion stabilizer was reported previously. 6 Briefly, ibuprofen (20%-60% wt/wt) was dissolved in a dichloromethane (5 mL) solution of polystyrene at 15-C and was emulsified at 400 rpm in 150 mL of methylcellulose solution (0.10% wt/vol) (pH 1.4) and stirred for 2 hours. The resulting microparticles were poured into 600 mL of cold distilled water, and the stirring was continued for a further 2 hours. The microparticles were filtered, washed with water, and vacuum-dried.
Sizing of the Microparticles
Microparticles were separated into different size fractions by sieving for 15 minutes on a mechanical shaker using a nest of standard sieves (Endecotts Ltd, London, UK) stacked from bottom to top in ascending order of aperture sizes ranging from 177 to 600 μm. In the current study, microparticles with a diameter of 275 µm were used for further investigations.
Ibuprofen Content Determinations in Various Formulations
For single-unit tablet and sustained-release capsule formulations, the drug content determination was done using the method described in USP, 7 whereas for multiple-unit formulations, the drug content determination was performed by an extraction method reported previously. 6 
Thin-Layer Chromatography
Qualitative thin-layer chromatography (TLC) was performed using 10 × 10 cm precoated silica gel 60 aluminum-backed TLC sheets with layer thickness of 0.25 mm. A dichloromethane solution of an accurately weighed amount of ibuprofen and an equivalent amount of ibuprofen present in single-unit and multiple-unit formulations was applied, using a sample applicator (Camag Nanomet 11 with 1-µL capillary and holder, CAMAG, Berlin, Germany), directly onto the TLC sheet, leaving 2 cm between this area and the edge. The sheet was developed with a benzene-etherglacial acetic acid-methanol (120 + 60 + 18 + 1) 8 system in a Camag chamber for 20 minutes. After development, the sheet was air-dried and placed in a UV cabinet. The spots were inspected against short-wave UV light (254 nm) in daylight using a glass filter for protection of the eyes against reflected short-wave UV light. From the following relationship, the R f value was calculated: R f ¼ distance traveled by samples ðsubstanceÞ distance traveled by solvent front ð1Þ
The experiment was duplicated under the identical conditions.
In Vitro Dissolution
The dissolution study was conducted following the USP paddle method Apparatus 2 in a USP XXI dissolution rate test apparatus (Campbell Electronics, Mumbai, India). The dosage forms, ibuprofen conventional tablet (400 mg), sustained-release ibuprofen (Fenlong-SR) capsules (400 mg), or ibuprofen-loaded polystyrene microparticles equivalent to 400 mg of the drug, were placed in a dissolution flask containing 900 mL of USP phosphate buffer solution of pH 6.8 at 37 ± 1-C and stirred with a paddle at 75 rpm. Samples were withdrawn (10 mL) at predetermined time intervals, and sink conditions were maintained by constantly replenishing with the same volume of fresh buffer solution. After suitable dilution, samples were analyzed in a double-beam spectrophotometer (Model 200-20, Hitachi, Japan) at 220 nm using the same buffer solution of pH 6.8 as blank.
Kinetics of Drug Release
In spite of significant compositional and structural differences between the single-unit and multiple-unit dosage forms, the in vitro dissolution data obtained from these studied formulations were fitted in various model equations for assessing the kinetics of ibuprofen release. The model for diffusion-controlled release given by Higuchi 9 is 100 À M ¼ Kt 1=2 , where M is the percentage of drug undissolved, K the dissolution rate constant, and t the time of dissolution. The equation proposed by Bamba et al, 10 ln M ¼ Kt, assumes that the drug molecules diffuse out through a dissolving gel-like layer formed around the drug during the dissolution process. The variables M, K, and t in the equation refer, respectively, to the percentage of drug undissolved, the dissolution rate, and the time of dissolution. The equation m 0 1=3 À m 1=3 ¼ Kt, proposed by Hixson and Crowell 11 for the dissolution of powder, assumes that the dissolution of powders is independent of the initial particle diameter (where m o in the equation is the initial drug concentration, m is the amount of drug left undissolved at time t, and K is the dissolution rate constant). The first-order model as adopted by Shah et al 12 is given by F ¼ 1 À e ÀKt , where F is the fraction of the drug dissolved at time t and K is the dissolution rate constant. The percent ibuprofen released from single-unit and multipleunit formulations was plotted against time on a log-log scale and analyzed for linearity using the least-squares method. The correlation coefficients were calculated and used to find the fitness of the data.
Stability Studies
Stability studies were conducted on polystyrene microparticles containing 30% wt/wt ibuprofen to assess drug stability with respect to drug content and drug release characteristics after storing the multiple-unit formulation in drug stability testing chambers (Campbell Electronics, Mumbai, India) at 2 different conditions for up to 6 months. Typical stresses are 25-C at 75% relative humidity to represent temperate conditions and 38-C at 90% relative humidity to represent tropical conditions. 13 Drug stability testing chambers containing a saturated aqueous solution in contact with an excess of a definite solid phase at a given temperature to maintain constant humidity in an enclosed space were used. The saturated salt solutions and temperatures used in this study were NaCl at 25-C and ZnSO 4 . 7H 2 O at 38-C to represent 75% and 90 ± 5% relative humidity, respectively.
In Vivo Study
The oral bioavailability studies were performed on volunteers in a single-dose crossover design. Four healthy human volunteers (2 males and 2 females, age 22.75 ± 1.50 years, weight 50.75 ± 4.87 kg), who were fully informed of the purpose and the procedure of this study, gave their consent to participate. The study protocol, which complied with the recommendations of the Helsinki Declaration, was fully approved by the institutional review board committee prior to the start of work with the human volunteers. For ethical reasons, the number of subjects was limited to 4. The biochemical examination of the volunteers revealed normal function of the kidney and liver. Use of other medication was not allowed before or during the study, to reduce intraor intersubject variability. On 3 different occasions, the subjects were separately allocated single oral doses of ibuprofen conventional tablet, Fenlong-SR capsule, or optimized ibuprofen (30% wt/wt)-loaded polystyrene microparticles equivalent to 400 mg of ibuprofen. Each of the 3 occasions was separated by a washout period of at least 10 days. To minimize gastric irritation, the subjects were provided a light breakfast (3 pieces of butter toast, 1 banana, and 50 mL milk) 30 minutes before each dosing, followed by a morning snack (2 crackers and 1 banana) 2.5 hours after dosing and a standard vegetarian lunch 4.5 hours after dosing. Blood samples (3 mL), withdrawn from a cubital vein at 0, 1, 2, 3, 4, 5, 6, 7, 8, 12, and 24 hours, were collected in centrifuge tubes containing 0.1 mL of 50% (wt/vol) sodium citrate solution. The samples were centrifuged and the separated plasma samples were stored at -40-C until analysis by highperformance liquid chromatography (HPLC).
Estimation of Ibuprofen in the Plasma of Human Volunteers
In the present study, plasma ibuprofen concentration in human volunteers was determined by an HPLC method of Adeyeye and Price 14 with a derivation as adopted by Lamprecht et al. 15 The Kontron HPLC system consisted of a Kontron 420 pump, a UV detector 332, and an autosampler 360 (Kontron Instruments, Zurich, Switzerland) equipped with a Rheodyne sample injector with a 50-μL sample loop. A reversed-phase 12.5 cm × 4.6 mm LiChrospher 100 RP-18 (5 μm) column furnished by Merck Co (Darmstadt, Germany) was used. The mobile phase consisted of acetonitrile: water:acetic acid 500:477:3 (premixed). The solvent flow rate was 0.8 mL/min. The analytical column and the guard column were kept inside a column heater held at 50-C.
A 0.3-mL volume of plasma was diluted with 1 mL of 0.2M phosphate buffer (pH 2.0), and 5 mL of diethyl ether was added. The mixture was shaken for 3 minutes and centrifuged at 15 000 rpm for 15 minutes. The ether layer was collected, and the aqueous layer was again extracted with 5 mL of ether. The ether layer was added to that obtained previously. The ether phase was evaporated to dryness, the residue was dissolved in the mobile phase, and 50-µL aliquots were injected into the HPLC system. The eluent was detected by the UV detector at 220 nm, and the sensitivity range of the detector was set at 0.0001 AUFS (absorption units full scale). The calibration curve equation was set up by spiking the drug-free plasma (derived from the blood collected at time 0) with varying amounts of ibuprofen (10-200 µg/mL) and a fixed quantity of internal standard (1 µg) and treating the plasma as described above. The peak area ratio of ibuprofen to internal standard (flurbiprofen) was obtained for each calibration standard. Ratios were fitted by least-squares regression to a linear calibration model. A good linear relationship (r 2 = 0.9996) was observed between the peak area ratio and the plasma concentration of ibuprofen in the range of 20 to 200 µg/mL. The lower detection limit was determined to be 10 µg/mL. The interday and intraday variation was found to be less than 2.8% coefficient of variation for the HPLC method. Recovery of ibuprofen was found to be 96.8% to 99.3%.
Pharmacokinetic Parameters
Estimates of pharmacokinetic parameters were obtained from the plasma concentration versus time data. The maximum concentration (C max ) and the time to reach the maximum concentration (T max ) were directly read from the plasma concentration versus time data as a measure of the rate of absorption. The apparent terminal elimination rate constant (K e ) was calculated using the least-squares regression analysis of the terminal portion of the log plasma concentration versus time profile, and the absorption rate constant (K a ) was calculated from the same plot by the method of residuals. 16 The absorption and elimination halflives (t 1/2a and t 1/2e ) were calculated by dividing 0.693/K a and 0.693/K e , respectively. The area under the concentrationtime curve (AUC) up to the last sampling point was determined by the trapezoidal method, 17 and the AUC beyond the last observed plasma concentration (C n ) was extrapolated to C n /K e .
Moment Analysis Parameters
The area under the first moment curve, the mean residence time (MRT), and the mean absorption time (MAT) were calculated by means of moment analysis.
18
In Vitro-In Vivo Modeling
Ibuprofen plasma levels were converted to percentage ibuprofen absorbed by the use of the modified Wagner-Nelson equation for the single compartment model 19 :
where C (t) is the plasma concentration at time t, K e is the elimination rate constant, AUC 0→ t is the area under the curve from 0 to time t, and AUC 0→∞ is the area under the curve from 0 to infinity, ∝. The in vivo absorption values were directly related to the in vitro dissolution data to complete the IVIVC.
Statistical Analysis
The student's t test procedure was employed to determine the variability of each parameter, as well as any differences existing between reference and test formulations. A P value of G .001 was considered statistically significant.
RESULTS AND DISCUSSION
Optimization of Polystyrene Microparticles Figure 1 shows the release behavior of 20% to 60% wt/wt ibuprofen-loaded polystyrene microparticles together with a conventional tablet formulation in phosphate buffer solution of pH 6.8. While 100% dissolution of the conventional tablet formulation occurred within 20 minutes, release of the drug from the microparticles extended over different periods of time depending on the initial drug loading. However, among the different formulations, 30% wt/wt drugloaded microparticles appeared to be equivalent in vitro to the Fenlong-SR formulation (r 2 = 0.9916) (Figure 2 ).
The R f value of the drug obtained from the single-unit and multiple-unit dosage forms was the same as that of the pure drug (data not shown). The qualitative TLC results thus revealed that the drug was compatible with the formulation excipients, and neither decomposition of the drug nor drugexcipient interaction occurred in any tested formulation.
The drug release kinetics, assessed by 4 different model equations, were also found to vary depending on ibuprofen load in polystyrene microparticles (Table 1) . From 20% wt/wt to 50% wt/wt drug load, the release rates determined by Higuchi's square root model showed higher correlation coefficient values than the correlation coefficient values of other models. A similar observation was seen for the Fenlong-SR capsules. This indicates that ibuprofen release from 20% to 50% drug-loaded microparticles and from Fenlong-SR capsules best followed a diffusion-controlled mechanism. However, when the drug load in the microparticles was 60% wt/wt, the release rates calculated by Hixon-Crowell's cube root model showed higher correlation coefficient values compared with the correlation coefficient 
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values of other models. The same observation was made for the conventional tablet formulation. It is known that there was no release-retarding barrier effect due to the excipients used in the manufacture of conventional tablets. Although a polymeric matrix was available to control the drug release, the amount of drug per unit polymer matrix was high in the case of 60% wt/wt ibuprofen-loaded polystyrene microparticles, as reported in our previous study. In that study, we showed through scanning electron microscopy that microparticles containing more than 50% drug were collapsed in nature and the polymeric film around the microparticles appeared to be discontinuous, exposing the drug particles directly to the dissolution medium. 20 Therefore, these last 2 formulations followed a simple powder mechanism over the time period of the dissolution study (Table 1) .
To further investigate whether 30% drug-loaded microparticles were equivalent in vitro to the Fenlong-SR, the MRT in vitro values, estimates of statistical mean of the times in which the mass of the drug remains as such in the formulation without undergoing dissolution, 21 were calculated and are given in Table 2 . Since the calculated values of MRT in vitro of both the formulations were almost the same, the 30% ibuprofen-loaded microparticles could be considered an optimized formulation. Therefore, that formulation was subjected to stability study and in vivo study in human volunteers.
Stability Study
The actual drug content in 30% wt/wt drug-loaded polystyrene microparticles stored in stability test chambers over a period of 6 months at 2 different storage conditions (25-C at 75% relative humidity and 38-C at 90% relative humidity) did not vary significantly. No significant variation was observed in the time required for 50% drug release (t 50% ), in minutes, from 30% drug-loaded polystyrene microparticles stored in identical storage conditions (data not shown). †Values represent mean ± SD, n = 3. ‡Values represent mean ± SD, n = 4.
In Vivo Study Figure 3 shows the mean plasma concentrations of ibuprofen attained following oral administration of conventional tablets, Fenlong-SR capsules, and optimized ibuprofen-loaded microparticles. While the mean plasma concentration value for the conventional tablet formulation was quick to reach a maximum, then fell rapidly, the Fenlong-SR capsules and optimized microparticles were slow to attain a maximum and slow to fall. Furthermore, Fenlong-SR and optimized microparticles maintained the minimum effective concentration, 10 μg/mL, 22 of ibuprofen throughout the study period. This indicates the continuing therapeutic equivalency of these formulations.
Pharmacokinetic parameters derived from the plasma ibuprofen data are summarized in Table 3 . Significantly higher C max (P G .001), K a (.01 G P G .05), and K e (P G .001) and lower T max (P G .001), t 1/2a (.001 G P G .10), t 1/2e (P G .001), and AUC 0→∞ (.001 G P G .01) were noted with the conventional tablet formulation. With the exception of K a , all the parameters of optimized ibuprofen-loaded microparticles were significantly lower than those obtained from the Fenlong-SR formulation (analysis of variance). The extent of absorption (bioavailability) was significantly higher (P G .01) with the Fenlong-SR formulation, as seen from the AUC 0→∞ (491.2 μg.h.mL −1 ), followed by the optimized formulation (311.3 μg.h.mL −1 ) and the conventional tablet formulation (160.7 μg.h.mL −1 ). When the AUCs obtained from the Fenlong-SR or optimized formulations were divided by the AUC obtained from the conventional formulation, the relative bioavailability (F) values for both the formulations were obtained ( Table 3 ). The relative bioavailability (F) value of the optimized ibuprofenloaded microparticles was low when compared with that of the Fenlong-SR formulation but was high when compared with that of the conventional formulation. The mean dissolution time (MDT) in vivo, an estimate of the mean time during which a drug molecule remains as a solid in the gastrointestinal tract, was calculated following the equation described by Riegelman and Collier
where MRT solution for ibuprofen (solution) is 2.63 hours. 24 The MDT in vivo obtained for the optimized formulation (Table 2 ) also showed a lower value than that obtained for the Fenlong-SR formulation. Similarly, the MAT calculated for the optimized formulation was low compared with the calculated value for the Fenlong-SR formulation but high compared with that calculated for the conventional Relative bioavailability when compared with conventional formulation.
formation (Table 2) . Furthermore, the retard quotient (R Δ ) values, which measure the sustaining/controlling efficacy of the formulation, were calculated for the microparticles and the Fenlong-SR formulations from half-value duration (HVD) analysis 25 and are shown in Table 2 . A higher R Δ value represents more retardation, whereas a lower R Δ value indicates less retardation. However, in this study, the R Δ value obtained for optimized and Fenlong-SR formulations was significantly different at the P level of .05 and was insignificant at the P level of .01. In summary, after thorough interpretation of AUC 0→∞ , F, MAT, MDT, R Δ , and pharmacokinetic parameters, with the exception of K a , it was apparent that the optimized ibuprofen-loaded microparticles showed lesser values to those of corresponding values of the Fenlong-SR formulation. The lower AUC 0→∞ , F, MAT, MDT, R Δ , and pharmacokinetic parameters, with the exception of K a , may be attributed either to lower sustaining/ controlling efficacy of the optimized formulation or to the variations among the physiological parameters (eg, food, gastric pH, gastric emptying time, gastric motility, rate of blood flow, rate of metabolism) 26 of the selected volunteers. A third alternative could be considered as the probability that the in vitro dissolution match, using the method selected, is not a good indicator of bioavailability in vivo for these particular formulations, it means that the selected dissolution method is probably not sensitive enough to indicate differences in mechanism of release between the tested formulations. Also, study power (by the total number of participants and by involving different sexes) may have been too low to detect reasons for differences.
IVIVC
Over the past decade, the Biopharmaceutics Classification System (BCS) approach, a regulatory guidance for conventional immediate-release products, is increasingly becoming an integral part of the development of bioequivalence studies, with special interest for BCS Class I and II drugs/ their products. Since this study focuses on ibuprofen, a BCS Class II drug, 27 dissolution is the rate-limiting step in the drug absorption and consequent bioavailability. In other words, if the product's rate of dissolution is the limiting factor in drug absorption, rate of dissolution should serve as a true predictor of the product's bioavailability. To assess the viability and the validity of the controlling nature of polystyrene microparticles in comparison to Fenlong-SR, an IVIVC study is essential since prolonged-release products may be especially suited for this kind of study. 28 Furthermore, the low aqueous solubility and the poor wettability of ibuprofen 29 may lead to bioavailability problems; bioavailability is likely to be rate-limited by the product's dissolution. By developing and evaluating an IVIVC study, one may be able to establish the dissolution test as a surrogate for human bioequivalence studies. In addition, one may reduce the number of bioequivalence studies performed during the initial US Food and Drug Administration approval process as well as reducing certain scaleup and postapproval changes (eg, formulation, equipment, process, manufacturing site changes). 30 When the percentage of ibuprofen released in pH 6.8 from optimized or Fenlong-SR formulations using the USP paddle method was plotted against the percentage of ibuprofen absorbed, calculated from Equation 2, a linear correlation was obtained (Figure 4 ). The regression line was calculated without an intercept by using linear regression analysis: y ¼ ð1 :8409Þx, for the optimized formulation (r 2 = 0.9668); and y ¼ ð0 :5162Þx, for the Fenlong-SR formulation (r 2 = 0.9999). This study indicates the correlation between the percentages dissolved in vitro and absorbed in vivo. A similar result has been reported for ibuprofen capsules in a dissolution medium of pH 6.6 using the JP XII paddle method versus absorption in dog. 31 However, the current study shows that the slope for the optimized microparticles formulation appears to be 3 times that of the Fenlong-SR formulation, so while there may be correlations in vivo to in vitro within a single dosage form, it seems that the 2 dosage forms are not equivalent in rates of absorption. To substantiate further the IVIVC, the following in vitro and in vivo parameters were considered to correlate. Time to dissolve 50% and 90% are correlated better with T max and C max , respectively, which corresponds to the rate of absorption, and time to dissolve 90% is better correlated with AUC 0→∞ , which reflects the extent of absorption.
32 Table 4 shows the comprehensive list of these correlations along with correlations of other in vitro and in vivo parameters that were done by linear regression analysis. Since all the selected parameters, including MRT in vitro and MRT in vivo , showed statistically significant correlations (r 2 9 0.9), the relatively simple procedure of monitoring the dissolution profile should allow the prediction of in vivo bioavailability, 21 although IVIVC could be improved by exploring a wider variety of dissolution conditions. 33 
CONCLUSION
This work revealed that ibuprofen-loaded polystyrene microparticles prepared by the emulsion-solvent evaporation method provided a new prolonged-release dosage form with improved bioavailability in comparison to that of a conventional tablet formulation. While the duration and intensity of ibuprofen released, in vitro, from the optimized and Fenlong-SR formulations were almost identical in the dissolution apparatus used, the rate and extent of drug absorption following single-dose oral administration of the optimized ibuprofen-loaded polystyrene microparticles appeared to be lower than that of the Fenlong-SR formulation.
